Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib plus toripalimab in hepatobiliary malignant tumors
NCT04010071Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2020
- Primary completion
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of axitinib, toripalimab in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), ampullary carcinoma, gallbladder carcinoma, mixed carcinoma, sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
axitinibtoripalimab
03
Conditions
hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)ampullary carcinomagallbladder carcinomamixed carcinoma
Beyond the preview
Go deeper on NCT04010071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04010071.